PDL BioPharma (PDLI) has an average broker rating of 3, which is interpreted as a Hold, as rated by 2 equity analysts. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
PDL BioPharma (PDLI) : Average target price received by PDL BioPharma (PDLI) is $3.75 with an expected standard deviation of $0.35. The most aggressive target on the stock is $4, whereas the most downbeat target is $4. 2 financial analysts are currently covering the stock.
PDL BioPharma (NASDAQ:PDLI): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $3.06 and $3.04 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $3.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $3.18, notching a gain of 2.91% for the day. The total traded volume was 1,396,339 . The stock had closed at $3.09 on the previous day.
The company shares have dropped -48.59% from its 1 Year high price. On Jul 16, 2015, the shares registered one year high at $6.63 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $3.21 and the 200 Day Moving Average price is recorded at $3.26.
PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.